US growth slumps again as recession fears mount

The US economy contracted for a second consecutive quarter – a technical recession – as inventory rundowns and a plunge in residential construction offset decent trade figures and rising consumer spending. Officials will say this isn't a 'real' recession, but with the squeeze on households intensifying, it is only going to be a matter of time

US second quarter GDP contracted at a 0.9% annualised rate after a 1.6% annualised drop in the first quarter

US in technical recession

So we have technical recession in the US with 2Q GDP contracting at a 0.9% annualised rate after a 1.6% annualised drop in the first quarter. The consensus had been expecting growth of 0.4%. The main reason was a big unwind in inventories which knocked two percentage points off the headline growth rate while residential investment contracted 14% annualised (subtracting 0.7pp off headline growth).

We also saw weakness in business capex (non-residential fixed investment fell 0.1%) and consumer spending growth slowed to just 1%. The only good news in this report is the rebound in net trade which contributed +1.4 percentage points to the headline growth rate.

Contributions to US GDP growth



Source: Macrobond, ING

The 'real' pain is still to come

While this is a technical recession, the Fed is correct to say we aren't in a "real" recession yet since unemployment is still falling and consumers are still spending, but it appears to be only a matter of time. We are hopeful of a decent rebound in 3Q GDP of the order of 2% given ongoing improvements in the trade numbers and a rebound in the inventory contribution, but once again this will mask what is happening in domestic demand.

Consumers remain under real pressure as inflation puts the squeeze on spending power while the plunge in equity markets is another factor weighing on sentiment. We are starting to see a drift lower in some of the people movement data such as Google mobility tracking around retail and recreation, OpenTable restaurant dining numbers and also the TSA airport security check numbers. Residential investment is set to become an increasing drag on activity as housebuilders react to falling transactions and a deteriorating outlook while corporate capex is set to slow as companies worry more about recession risks.

US real GDP levels versus Eurozone



Source: Macrobond, ING

Hikes for now, but rate cuts will be the 2023 story

With interest rates continuing to rise, the dollar providing more of a headwind and credit spreads widening out recessionary forces are undoubtedly intensifying. Should the housing market topple over and prices start to fall this will add to the pessimism.

For now though, the focus is inflation and the Federal Reserve has made it clear it is prepared to sacrifice growth to get inflation back to target. But by having delayed tightening for too long they are playing catch-up and may well end up having to reverse course next year. Historically the gap between the last rate hike and the first rate cut is six months. It could happen even more quickly this time around.

US budget deal

There are a lot of headlines, quite rightly, surrounding the apparent agreement between holdout Senator Joe Manchin and his Democrat Senate colleagues surrounding money for climate change investment programs, prescription drug charges and extending healthcare subsidies. Listed as a $400bn spending commitment over the next ten years this will be more than fully funded by $739bn of tax revenue gains, most notably through a 15% minimum corporate tax rate and greater IRS enforcement.

The assumption is that this will meet the criteria to be voted on under budget reconciliation rules, so only a simple majority in the Senate would be required. We assume this should pass given Vice President Kamala Harris has the deciding vote in the 50-50 split Senate – the Republicans will likely unanimously vote against given the proximity to mid-term elections and the potential lift passing the bill would give the Democrats. The one stumbling block could come from Arizona Democrat Kyrsten Sinema who has stood in the way of previous proposals, but we suspect she will fall in line with the House Democrats broadly backing the proposals.

It sounds impressive, but the important point is that this will be spread over 10 years and will barely move the needle in terms of its immediate growth implications. Nonetheless, the prescription drug charges are an important story that will limit the upside for inflation – finally a bit of good news for the Fed.

Author

James Knightley
Chief International Economist
james.knightley@ing.com

Disclaimer

This publication has been prepared by the Economic and Financial Analysis Division of ING Bank N.V. ("**ING**") solely for information purposes without regard to any particular user's investment objectives, financial situation, or means. *ING forms part of ING Group (being for this purpose ING Group N.V. and its subsidiary and affiliated companies).* The information in the publication is not an investment recommendation and it is not investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument. Reasonable care has been taken to ensure that this publication is not untrue or misleading when published, but ING does not represent that it is accurate or complete. ING does not accept any liability for any direct, indirect or consequential loss arising from any use of this publication. Unless otherwise stated, any views, forecasts, or estimates are solely those of the author(s), as of the date of the publication and are subject to change without notice.

The distribution of this publication may be restricted by law or regulation in different jurisdictions and persons into whose possession this publication comes should inform themselves about, and observe, such restrictions.

Copyright and database rights protection exists in this report and it may not be reproduced, distributed or published by any person for any purpose without the prior express consent of ING. All rights are reserved. ING Bank N.V. is authorised by the Dutch Central Bank and supervised by the European Central Bank (ECB), the Dutch Central Bank (DNB) and the Dutch Authority for the Financial Markets (AFM). ING Bank N.V. is incorporated in the Netherlands (Trade Register no. 33031431 Amsterdam). In the United Kingdom this information is approved and/or communicated by ING Bank N.V., London Branch. ING Bank N.V., London Branch is authorised by the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. ING Bank N.V., London branch is registered in England (Registration number BR000341) at 8-10 Moorgate, London EC2 6DA. For US Investors: Any person wishing to discuss this report or effect transactions in any security discussed herein should contact ING Financial Markets LLC, which is a member of the NYSE, FINRA and SIPC and part of ING, and which has accepted responsibility for the distribution of this report in the United States under applicable requirements.

Additional information is available on request. For more information about ING Group, please visit http://www.ing.com.